Chouinard 1984.

Methods	Allocation: randomised, stratified by sex & past frequency of depot administration. Blindness: double. Duration: 8 months. Statistics: last observation carried forward.
Participants	Diagnosis: schizophrenia (DSM III). History: on depot >3 months, duration ill ‐ mean 16 yrs, range 3‐38, informed consent given. N=72. Age: mean 44 yrs, range 18‐66. Sex: 36 M, 36 F. Setting: community.
Interventions	1. Haloperidol decanoate: dose mean 225mg/injection, 2‐4 weekly, range 15‐900mg/injection. N=36. 2. Fluphenazine decanoate: dose mean 75mg/injection, 2‐4 weekly, range 2.5‐300mg/injection. N=36.
Outcomes	Global Impression (CGI). Mental state (BPRS). Leaving the study early. Additional medication. Unable to use ‐ Side effects (ESRS ‐ authors own scale*, TESF ‐ no data reported). Physiological measures (prolactin, drug plasma levels ‐ non clinical outcomes, data not usable).
Notes	* Marshall et al, 1998.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear